

R1.126

92

~~141.~~ (new)

A pharmaceutically acceptable formulation comprising human FSH and benzyl alcohol in an aqueous diluent.

93.

~~142.~~ (new)

The formulation of Claim ~~141~~<sup>92</sup>, wherein the human FSH is produced through the use of recombinant DNA technology.

94.

~~143.~~ (new)

The formulation of Claim ~~142~~<sup>92</sup>, wherein the human FSH is at a concentration of about 5.0 µg/mL to about 200 µg/mL.

95.

~~144.~~ (new)

The formulation of Claim ~~143~~<sup>94</sup>, wherein the human FSH is at a concentration of 50 µg/mL to about 200 µg/mL.

96.

~~145.~~ (new)

The formulation of Claim ~~144~~<sup>95</sup>, further comprising sodium phosphate.

97.

~~146.~~ (new)

The formulation of Claim ~~145~~<sup>96</sup>, wherein the concentration of benzyl alcohol is 10 mg/mL.

98.

~~147.~~ (new)

The formulation of Claim ~~146~~<sup>94</sup>, further comprising sodium phosphate.

99.

~~148.~~ (new)

The formulation of Claim ~~147~~<sup>98</sup>, wherein the concentration of benzyl alcohol is 10 mg/mL.

100.

~~149.~~ (new)

The formulation of Claim ~~148~~<sup>93</sup>, further comprising sodium phosphate.

101.

~~150.~~ (new)

The formulation of Claim ~~149~~<sup>100</sup>, wherein the concentration of benzyl alcohol is 10 mg/mL.

102.

~~151.~~ (new)

The formulation of Claim ~~150~~<sup>92</sup>, further comprising sodium phosphate.